Stanley Laman Group Ltd. bought a new stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,080 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. TD Asset Management Inc. raised its holdings in Ultragenyx Pharmaceutical by 28.3% during the second quarter. TD Asset Management Inc. now owns 83,170 shares of the biopharmaceutical company’s stock worth $5,281,000 after purchasing an additional 18,350 shares in the last quarter. Sector Gamma AS raised its stake in Ultragenyx Pharmaceutical by 20.8% during the 2nd quarter. Sector Gamma AS now owns 79,653 shares of the biopharmaceutical company’s stock valued at $5,058,000 after purchasing an additional 13,718 shares during the period. Aperio Group LLC raised its stake in Ultragenyx Pharmaceutical by 21.4% during the 2nd quarter. Aperio Group LLC now owns 9,130 shares of the biopharmaceutical company’s stock valued at $580,000 after purchasing an additional 1,608 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Ultragenyx Pharmaceutical by 6.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 212 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 12.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,511 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 515 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently issued reports on RARE shares. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, July 18th. Barclays reissued a “buy” rating and set a $87.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Sunday, August 4th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday. Wedbush reaffirmed a “buy” rating and set a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday. Finally, Morgan Stanley dropped their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $75.93.

Shares of NASDAQ:RARE traded down $1.40 during midday trading on Thursday, hitting $58.29. The stock had a trading volume of 6,093 shares, compared to its average volume of 446,176. The stock has a 50-day moving average price of $60.32. The company has a market capitalization of $3.55 billion, a P/E ratio of -8.01 and a beta of 2.16. The company has a quick ratio of 9.14, a current ratio of 9.32 and a debt-to-equity ratio of 0.04. Ultragenyx Pharmaceutical Inc has a fifty-two week low of $37.44 and a fifty-two week high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 527.49% and a negative return on equity of 49.84%. The business had revenue of $24.15 million during the quarter, compared to analysts’ expectations of $22.16 million. During the same period in the prior year, the company earned ($1.06) EPS. The firm’s quarterly revenue was up 88.8% compared to the same quarter last year. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -7.04 earnings per share for the current fiscal year.

In other news, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $63.01, for a total value of $93,821.89. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 7.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.